Mesothelioma

Dr. Giovanni Selvaggi, Who Has Brought Several Oncology Drugs to Market, Joins CEL-SCI as Clinical Advisor

Retrieved on: 
Thursday, June 6, 2024

CEL-SCI Corporation (NYSE American: CVM) today announced Dr. Giovanni Selvaggi, an oncology key opinion leader instrumental in successfully bringing several drugs to market has joined CEL-SCI as a Clinical Advisor.

Key Points: 
  • CEL-SCI Corporation (NYSE American: CVM) today announced Dr. Giovanni Selvaggi, an oncology key opinion leader instrumental in successfully bringing several drugs to market has joined CEL-SCI as a Clinical Advisor.
  • View the full release here: https://www.businesswire.com/news/home/20240606671425/en/
    Multikine is the first investigational pre-surgical cancer drug in newly diagnosed head and neck cancer.
  • He is also a Clinical Consultant to Tubulis GmBH for a first-in-class ADC program in solid tumors, and Clinical Strategy Senior Advisor to Alira Health.
  • Selvaggi has a passion for bringing cancer drugs to market to save lives and lead clinical research toward a cure for cancer.

Oregon Jury Awards $260 Million in Mesothelioma Case Against Johnson & Johnson

Retrieved on: 
Tuesday, June 4, 2024

A jury in Portland, Ore., has found in favor of a mother of three suffering from the deadly cancer mesothelioma and ordered Johnson & Johnson to pay her $260 million.

Key Points: 
  • A jury in Portland, Ore., has found in favor of a mother of three suffering from the deadly cancer mesothelioma and ordered Johnson & Johnson to pay her $260 million.
  • Kyung Lee, 49, of Beaverton, Ore., has used Johnson & Johnson cosmetic products throughout her lifetime and now suffers from the incurable cancer.
  • Mesothelioma is a cancer of the lining of the lungs caused by exposure to asbestos.
  • The jury awarded $60 million in compensatory damages and $200 million in punitive damages.

RS Oncology Announces Positive Data from a Phase 1 Clinical Trial of RSO-021, a First-in-Class Therapeutic for Malignant Pleural Mesothelioma

Retrieved on: 
Monday, June 3, 2024

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240603559175/en/
    Professor Dean Fennell, principal investigator, presents results from the Phase 1 MITOPE clinical study of a first-in-human, and potential first-in-class therapeutic, RSO-021.
  • (Photo: Business Wire)
    The Phase 1 data was presented by Professor Dean Fennell, MRCP, FRCP (MD/PhD) on behalf of all the MITOPE investigators at an oral presentation session.
  • In the 15 recruited patients safety data demonstrated weekly treatment of RSO-021 was well tolerated at 90 mg.
  • The safety and efficacy observed in the Phase 1 trial is supported by strong pre-clinical rationale” said Brian Cunniff, PhD, Chief Science Officer for RS Oncology.

invoX Pharma Presents Positive Clinical Data from Phase 1 Study of FS222 in Patients with Advanced Solid Tumours at the 2024 American Society of Clinical Oncology Annual Meeting

Retrieved on: 
Monday, June 3, 2024

These preliminary findings were presented today at the 2024 American Society of Clinical Oncology Annual Meeting in Chicago as an oral presentation during the Development Therapeutics – Immunology Session.

Key Points: 
  • These preliminary findings were presented today at the 2024 American Society of Clinical Oncology Annual Meeting in Chicago as an oral presentation during the Development Therapeutics – Immunology Session.
  • FS222 is a novel tetravalent bispecific antibody, using invoX's proprietary Fcab® platform technology, that drives PD-L1 dependent CD137 agonism.
  • The data presented today are from 100 subjects in the ongoing first-in-human (FIH) dose-escalation phase 1 clinical trial of FS222 (NCT04740424) in patients with advanced solid tumours.
  • The study is designed to evaluate safety and identify the maximum tolerated dose, with secondary objectives related to anti-tumour activity, pharmacokinetics, and pharmacodynamics.

Oncovita and Institut Pasteur announce the creation of a joint laboratory dedicated to cancer immunotherapy and prophylactic vaccinology

Retrieved on: 
Wednesday, May 29, 2024

Paris, 29 May 2024 - Dedicated to the research of new immunotherapeutic vaccines in oncology and prophylactic vaccines for contagious diseases, the joint Institut Pasteur - Oncovita laboratory is aimed to design and develop vaccine candidates through to proof of concept in humans.

Key Points: 
  • Paris, 29 May 2024 - Dedicated to the research of new immunotherapeutic vaccines in oncology and prophylactic vaccines for contagious diseases, the joint Institut Pasteur - Oncovita laboratory is aimed to design and develop vaccine candidates through to proof of concept in humans.
  • Oncovita and the Institut Pasteur have already been working together for several years on the construction and development of new vaccines based on MeasovirR technology, based on the measles vaccine virus.
  • The production method in accordance with good manufacturing practice (GMP) is under development in order to initiate   the first clinical trial.
  • The joint Institut Pasteur - Oncovita laboratory will also be carrying out research into viral defective interfering RNAs (DI-RNAs) produced by modified recombinant measles viruses.

Bristol Myers Squibb Receives European Commission Approval for Opdivo® (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma

Retrieved on: 
Wednesday, May 29, 2024

Bristol Myers Squibb (NYSE: BMY) today announced that the European Commission (EC) has approved Opdivo® (nivolumab) in combination with cisplatin and gemcitabine for the first-line treatment of adult patients with unresectable or metastatic urothelial carcinoma (UC).

Key Points: 
  • Bristol Myers Squibb (NYSE: BMY) today announced that the European Commission (EC) has approved Opdivo® (nivolumab) in combination with cisplatin and gemcitabine for the first-line treatment of adult patients with unresectable or metastatic urothelial carcinoma (UC).
  • With this approval, Opdivo in combination with cisplatin and gemcitabine becomes the first concurrent immunotherapy-chemotherapy approved for the treatment of adult patients with unresectable or metastatic UC in the first-line setting in the European Union.
  • “With today’s approval by the EC, we’re pleased to be able to offer Opdivo concurrently with chemotherapy to eligible patients with unresectable or metastatic UC,” said Dana Walker, M.D., M.S.C.E., vice president and global program lead, gastrointestinal and genitourinary cancers, Bristol Myers Squibb.
  • “This is a major step forward for this patient population and reinforces our goal of advancing and delivering new options to patients with difficult-to-treat cancers.

Compass Therapeutics to Present Phase 1 Data for CTX-471, A Novel CD137 Agonist Antibody, Demonstrating Anti-Tumor Activity in Patients Who Have Progressed on Approved PD-1 or PD-L1 Inhibitors at the American Society of Clinical Oncology (ASCO) Annual Mee

Retrieved on: 
Thursday, May 23, 2024

Five clinical responses were observed, all in patients who previously received checkpoint inhibitors.

Key Points: 
  • Five clinical responses were observed, all in patients who previously received checkpoint inhibitors.
  • A durable partial response (PR) in a patient with small-cell lung cancer (SCLC) converted to a complete response, as confirmed by PET scan.
  • Four additional PRs were also observed, 3 of 11 (27.3%) patients with melanoma (2 confirmed, one unconfirmed) and one of four (25%) patients with mesothelioma (PR confirmed).
  • CTX-471 monotherapy was observed to be generally well-tolerated, with the majority of adverse events (AEs) being Grade 1-2.

Proposed Class Action Filed by Six Law Firms Alleging Series of Fraudulent Transfers by Johnson & Johnson in Talc Litigation

Retrieved on: 
Wednesday, May 22, 2024

The transfer of corporate assets from an existing consumer health division into a new entity known as Kenvue.

Key Points: 
  • The transfer of corporate assets from an existing consumer health division into a new entity known as Kenvue.
  • This spinoff formed in 2022 sought to create an additional, unlawful shield for J&J assets from litigation liability.
  • In a recent case involving Johnson & Johnson talc- and mesothelioma-related claims, a jury in Chicago held Kenvue liable, among others.
  • The plaintiffs in the proposed class are represented by attorneys with the law firms of Ashcraft & Gerel, Bailey Glasser, Beasley Allen, Burns Charest, Golomb Legal, and Levin Papantonio Rafferty.

R.T. Vanderbilt Tagged With $15 Million Mesothelioma Verdict by Connecticut Jury

Retrieved on: 
Friday, May 17, 2024

A Connecticut Superior Court jury has handed up a verdict of $15 million against R.T. Vanderbilt Holding Company Inc., on behalf of the family of a man who died of mesothelioma, a cancer of the lining of the lungs tied to asbestos exposure.

Key Points: 
  • A Connecticut Superior Court jury has handed up a verdict of $15 million against R.T. Vanderbilt Holding Company Inc., on behalf of the family of a man who died of mesothelioma, a cancer of the lining of the lungs tied to asbestos exposure.
  • Vanderbilt purchased International Talc in 1974 and continued the product line, making it responsible under Connecticut law for Mr. Barone’s death.
  • In Connecticut, once a jury determines punitive damages are appropriate, a decision on the amount is one the court makes at a later date.
  • vs. Blue M et al., case number FBT-CV-22-6116587S in Connecticut Superior Court at Bridgeport.

A2 Bio Announces First Patient Dosed in EVEREST-2 Phase 1 Clinical Trial of Novel Mesothelin Logic-Gated CAR T

Retrieved on: 
Thursday, May 16, 2024

A2 Biotherapeutics, Inc. (A2 Bio), a clinical-stage cell therapy company developing first-in-class logic-gated cell therapies for solid tumors, today announced dosing of the first patient in the Phase 1 clinical trial of A2B694.

Key Points: 
  • A2 Biotherapeutics, Inc. (A2 Bio), a clinical-stage cell therapy company developing first-in-class logic-gated cell therapies for solid tumors, today announced dosing of the first patient in the Phase 1 clinical trial of A2B694.
  • A2B694 is the second autologous cell therapy in clinical development by A2 Bio using its proprietary Tmod™ platform.
  • “Dosing our first patient in this trial is a key step to provide a precise, novel CAR T therapy to patients with solid tumors that express mesothelin with no curative treatment options.
  • All of us at A2 Bio would like to thank participating patients, investigators, and clinical care providers,” said Dr. William Go, chief medical officer of A2 Bio.